Key facts

Below are highlights of our performance over the last 12 months:

January 2016

Corvus announced as adenosine receptor antagonist licensee (deal previously announced in February 2015)

April 2016

Successful completion of CCP-08 pivotal single-dose comparative bioavailability study  

April 2016

Successful completion of CCP-07 pivotal multiple-dose comparative bioavailability study

May 2016

Successfully raised £40m (before expenses) in Placing through issue of 80m new Ordinary Shares at a Placing Price of 50p per share

May 2016

Suir Pharma, sole supplier for Moxatag® placed in provisional liquidation

July 2016

€500k milestone received following achievement of new milestone in first oncology drug discovery collaboration with Servier

July 2016

Successful completion of CCP-08 pivotal multiple-dose comparative bioavailability study

September 2016

FDA accepted CCP-07 for full review, with PDUFA date of 20 April 2017

December 2016

FDA accepted CCP-08 for full review, with PDUFA date of 4 August 2017

February 2017

$3m milestone received following achievement of a clinical milestone from collaboration with Corvus

March 2017

New two-year oncology drug discovery collaboration on undisclosed target entered with Servier, strengthening existing partnership

April 2016

Successful completion of CCP-08 pivotal single-dose comparative bioavailability study  

April 2016

Successful completion of CCP-07 pivotal multiple-dose comparative bioavailability study

May 2016

Successfully raised £40m (before expenses) in Placing through issue of 80m new Ordinary Shares at a Placing Price of 50p per share

May 2016

Suir Pharma, sole supplier for Moxatag® placed in provisional liquidation

July 2016

€500k milestone received following achievement of new milestone in first oncology drug discovery collaboration with Servier

July 2016

Successful completion of CCP-08 pivotal multiple-dose comparative bioavailability study

Sept 2016

FDA accepted CCP-07 for full review, with PDUFA date of 20 April 2017

Dec 2016

FDA accepted CCP-08 for full review, with PDUFA date of 4 August 2017

Feb 2017

$3m milestone received following achievement of a clinical milestone from its collaboration with Corvus

Mar 2017

New two-year oncology drug discovery collaboration on undisclosed target entered with Servier, strengthening existing partnership

Latest News

Results Announcement for the year ended 30 June 2017

Vernalis plc (LSE: VER) today announces its audited financial results for the year ended 30 June 2017, following the year-end trading update published on 18 July 2017.

 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch